Bardoxolone methyl inhibits the infection of rabies virus via Nrf2 pathway activation in vitro
Open Access
- 10 November 2023
- journal article
- research article
- Published by Springer Nature in Virology Journal
- Vol. 20 (1) , 1-15
Abstract
Background: Rabies is a widespread, fatal, infectious disease. Several antivirals against rabies virus (RABV) infection have been reported, but no approved, RABV-specific antiviral drugs that inhibit RABV infection in the clinic after symptom onset are available. Therefore, more effective drugs to reduce rabies fatalities are urgently needed. Bardoxolone methyl (CDDO-Me), an FDA-approved compound that has long been known as an antioxidant inflammatory modulator and one of the most potent nuclear factor erythroid-derived 2-like 2 (Nrf2) activators, protects myelin, axons, and CNS neurons by Nrf2 activation. Therefore, we investigated the potency of its anti-RABV activity in vitro. Methods: The mouse neuroblastoma cell line Neuro2a (N2a) and three RABV strains of different virulence were used; the cytotoxicity and anti-RABV activity of CDDO-Me in N2a cells were evaluated by CCK-8 assay and direct fluorescent antibody (DFA) assay. Pathway activation in N2a cells infected with the RABV strains SC16, CVS-11 or CTN upon CDDO-Me treatment was evaluated by western blotting (WB) and DFA assay. Results: CDDO-Me significantly inhibited infection of the three RABV strains of differing virulence (SC16, CVS-11 and CTN) in N2a cells. We also examined whether CDDO-Me activates the Nrf2-associated pathway upon infection with RABV strains of differing virulence. Nrf2, phosphorylated sequestosome (SQSTM1), SQSTM1, hemoglobin oxygenase (HO-1) and NAD(P)H dehydrogenase quinone 1 (NQO1) expression in N2a cells increased to varying degrees with CDDO-Me treatment, accompanied by Kelch-like ECH-associated protein 1 (Keap1) dissociation, upon infection with SC16, CVS-11 or CTN. The activation of SQSTM1 phosphorylation was significantly associated with the degradation of Keap-1 in CDDO-Me-treated N2a cells upon RABV infection. Furthermore, N2a cells pretreated with the Nrf2-specific inhibitor ATRA showed a significant decrease in HO-1 and NQO1 expression and a decrease in the anti-RABV efficacy of CDDO-Me. These inhibitory effects were observed upon infection with three RABV strains of differing virulence. Conclusion: CDDO-Me inhibited RABV infection via Nrf2 activation, promoting a cytoprotective defense response in N2a cells. Our study provides a therapeutic strategy for RABV inhibition and neuroprotection during viral infection.Keywords
All Related Versions
This publication has 67 references indexed in Scilit:
- Role of Nrf2 in Host Defense against Influenza Virus in Cigarette Smoke-Exposed MiceJournal of Virology, 2011
- Bardoxolone methyl (BARD) ameliorates ischemic AKI and increases expression of protective genes Nrf2, PPARγ, and HO-1American Journal of Physiology-Renal Physiology, 2011
- Hepatitis C Virus Impairs the Induction of Cytoprotective Nrf2 Target Genes by Delocalization of Small Maf ProteinsJournal of Biological Chemistry, 2011
- Hepatitis B Virus Induces Expression of Antioxidant Response Element-regulated Genes by Activation of Nrf2Journal of Biological Chemistry, 2010
- Role of Oxidative Stress in Rabies Virus Infection of Adult Mouse Dorsal Root Ganglion NeuronsJournal of Virology, 2010
- Nrf2:INrf2 (Keap1) signaling in oxidative stressFree Radical Biology and Medicine, 2009
- Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: Critical role for the astrocyteProceedings of the National Academy of Sciences, 2009
- Antiviral Activity of Nrf2 in a Murine Model of Respiratory Syncytial Virus DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Heme oxygenase-1 suppresses hepatitis C virus replication and increases resistance of hepatocytes to oxidant injuryHepatology, 2008
- Antioxidant Treatment Ameliorates Respiratory Syncytial Virus–induced Disease and Lung InflammationAmerican Journal of Respiratory and Critical Care Medicine, 2006